Schizophrenia Research
Volume 101, Issue 1 , Pages 273-286 , April 2008

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

  • Jonathan M. Meyer

      Affiliations

    • Department of Psychiatry, University of California, San Diego, United States
    • VA San Diego Healthcare System, United Statess
    • Corresponding Author InformationCorresponding author. San Diego VAMC, 3350 La Jolla Village Drive (116A), San Diego, CA 92161, United States. Tel.: +1 858 642 3570; fax: +1 858 552 7542.
    • ,
  • Vicki G. Davis

      Affiliations

    • Department of Biostatistics, Collaborative Studies Coordinating Center, University of North Carolina at Chapel Hill, Bank of America Center, 137 E. Franklin Street, Suite 400, Chapel Hill, NC 27514-4145, United States
    • ,
  • Donald C. Goff

      Affiliations

    • Department of Psychiatry, Harvard University, United States
    • Schizophrenia Program, Massachusetts General Hospital, Freedom Trail Clinic, Lindemann Mental Health Center, 25 Staniford St., Boston, MA 02114, United States
    • ,
  • Joseph P. McEvoy

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University, United States
    • Clinical Research, John Umstead Hospital, 1003 12th Street, Butner, NC 27509, United States
    • ,
  • Henry A. Nasrallah

      Affiliations

    • Psychiatry and Neuroscience, University of Cincinnati, 231 Albert Sabin Way, PO Box 670559, Cincinnati, OH 45267-0559, United States
    • ,
  • Sonia M. Davis

      Affiliations

    • Biostatistics, Quintiles Inc., 5927 South Miami Blvd, Morrisville, NC 27560, United States
    • ,
  • Robert A. Rosenheck

      Affiliations

    • Epidemiology and Public Health, Yale Medical School, United States
    • Child Study Center, Yale Medical School, United States
    • Northeast Program Evaluation Center, VA Connecticut Health Care System, 950 Campbell Ave, West Haven, CT 06516, United States
    • ,
  • Gail L. Daumit

      Affiliations

    • Epidemiology, and Health Policy and Management, Johns Hopkins Medical Institutions, 2024 East Monument Street, Suite 2-500, Baltimore, MD 21287, United States
    • ,
  • John Hsiao

      Affiliations

    • Adult Psychopharmacology Intervention Program, National Institute of Mental Health, Bethesda, MD, United States
    • ,
  • Marvin S. Swartz

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3173, Duke University Medical Center, Durham, NC 27710, United States
    • ,
  • T. Scott Stroup

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Campus Box 7160, Chapel Hill, NC 27599-7160, United States
    • ,
  • Jeffrey A. Lieberman

      Affiliations

    • Department of Psychiatry, Columbia University, Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, United States

Received 1 September 2007 ,Revised 6 December 2007 ,Accepted 22 December 2007.

References 

  1. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabetic Medicine. 2006;23:469–480
  2. American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30(Suppl 1):S42–S47
  3. American Diabetes Association , American Psychiatric Association , American Association of Clinical Endocrinologists , North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry. 2004;65:267–272
  4. American Heart Association , National Heart Lung and Blood Institute , Grundy SM, Cleeman JI, Daniels SR, Donato KA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiology in Review. 2005;13:322–327
  5. Assmann G, Guerra R, Fox G, Cullen P, Schulte H, Willett D, et al. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. American Journal of Cardiology. 2007;99:541–548
  6. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine. 2007;357:1301–1310
  7. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophrenia Research. 2007;90:162–173
  8. Bushe C, Holt R. Prevalence of diabetes and glucose intolerance in patients with schizophrenia. British Journal of Psychiatry. 2004;184:67–71
  9. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Canadian Journal of Psychiatry — Revue Canadienne de Psychiatrie. 2004;49:753–760
  10. De Hert MA, van Winkel R, van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research. 2006;83:87–93
  11. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA. 2001;285:2109–2113
  12. Dixon WJ. Simplified estimation from censored normal samples. Annals of Mathematical Statistics. 1960;31:385–391
  13. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults . Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  14. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004;173:309–314
  15. Girman CJ, Dekker JM, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, et al. An exploratory analysis of criteria for the metabolic syndrome and its prediction of long-term cardiovascular outcomes: the Hoorn study. American Journal of Epidemiology. 2005;162:438–447
  16. Goff DC, Sullivan L, McEvoy JP, Meyer JM, H.A.N. , Daumit G, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE Study and matched controls. Schizophrenia Research. 2005;80:45–53
  17. Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438
  18. Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia. 2006;49:49–55
  19. Hagg S, Lindblow Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. International Clinical Psychopharmacology. 2006;21:93–98
  20. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Journal of Clinical Psychiatry. 2006;67:789–797
  21. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, et al. Clozapine, diabetes mellitus, hyperlipidemia and cardiovascular risks and mortality: results of a 10-year naturalistic study. Psychiatry. 2005;66:1116–1121
  22. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32:289–297
  23. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study [see comments] [published erratum appears in Circulation 1998 May 19;97(19):1995] [see comments]. Circulation. 1998;97:1029–1036
  24. Kahn R, Buse J, Ferrannini E, Stern M. The Metabolic Syndrome: time for a critical appraisal. Diabetes Care. 2005;28:2289–2304
  25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine. 2005;353:1209–1223
  26. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program — Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30:8–13
  27. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry. 2004;161:1334–1349
  28. Mayer-Davis EJ, Levin S, Bergman RN, D'Agostino RB, Karter AJ, Saad MF, et al. Insulin secretion, obesity, and potential behavioral influences: results from the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes/Metabolism Research and Reviews. 2001;17:137–145
  29. McEvoy JP, Meyer JM, Nasrallah HA, Goff DC, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III. Schizophrenia Research. 2005;80:19–32
  30. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant.[see comment][summary for patients in Ann Intern Med. 2003 Nov 18;139(10):I16; PMID: 14623638]. Annals of Internal Medicine. 2003;139:802–809
  31. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. Journal of Clinical Psychiatry. 2002;63:425–433
  32. Meyer JM, Nasrallah HA. Medical illness and schizophrenia. In: Washington, D.C.: American Psychiatric Press, Inc.; 2003;p. 254
  33. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research. 2004;70:1–17
  34. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19:1–95
  35. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  36. Reaven GM. The metabolic syndrome: requiescat in pace. Clinical Chemistry. 2005;51:931–938
  37. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391–397
  38. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin M-R, Lauren LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort Study. Journal of Clinical Psychiatry. 2005;66:559–563
  39. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Archives of General Psychiatry. 2007;64:1123–1131
  40. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DSJ, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.[see comment]. Circulation. 2003;108:414–419
  41. Snijder MB, Visser M, Dekker JM, Seidell JC, Fuerst T, Tylavsky F, et al. The prediction of visceral fat by dual-energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2002;26:984–993
  42. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry. 2007;7:14
  43. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin. 2003;29:15–31
  44. Troisi RJ, Cowie CC, Harris MI. Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. JAMA. 2000;284:3157–3159
  45. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Archives of Internal Medicine. 2005;165:2644–2650
  46. Weiden PJ, Newcomer JW, Loebel A, Yang R, Lebovitz H. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. In: Neuropsychopharmacology Advance Online Publication, 18 July 2007. 2007;p. 1–10

☆ Supported by NIMH grant #N01MH90001.

PII: S0920-9964(08)00038-8

doi: 10.1016/j.schres.2007.12.487

Schizophrenia Research
Volume 101, Issue 1 , Pages 273-286 , April 2008

Article Tools

* Image Usage & Resolution